Intraoperative Fentanyl Dose on Respiratory Complications

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03198208
Collaborator
(none)
183,396
1
137.9
1329.7

Study Details

Study Description

Brief Summary

Fentanyl is the most commonly used opioid during anesthesia at Massachusetts General Hospital. Compared to other opioids, e.g. sulfentanil and remifentanil, fentanyl's pharmacokinetic properties are more problematic as the context sensitive half-time increases with duration of fentanyl infusion. This may lead to respiratory complications particularly in patients who receive fentanyl for surgical procedures of long duration. Considering the common use of fentanyl during surgery and its duration of action that is hard to predict during long surgical procedures, we will evaluate the association between intraoperative fentanyl dose and postoperative respiratory complications within 3 days of surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: Fentanyl dose administration

Detailed Description

Our team has conducted a series of studies to define the optimal anesthesia plan that minimizes the risk of postoperative respiratory complications. Opioids are almost always used in the perioperative management of patients undergoing surgery during anesthesia. Intraoperatively they are administered to achieve adequate surgical conditions. Opioids are respiratory depressants. They decrease dose-dependently the drive to the respiratory pump muscles and upper airway dilator muscles, which leads to respiratory acidemia and hypercapnia. Fentanyl is the most commonly used opioid during anesthesia at MGH. Compared to other opioids, e.g. sulfentanil and remifentanil, fentanyls pharmacokinetic is more problematic as the context sensitive half-life increases with duration of fentanyl administration. This may lead to respiratory complications. Considering the common use of fentanyl during surgery and its duration of action that is hard to predict during long surgical procedures, we will evaluate the association between intraoperative fentanyl dose and postoperative respiratory complications within 3 days of surgery.

To account for other factors that may affect the incidence of postoperative respiratory complications, we included the following confounder model in all of our analyses:

  • Gender

  • Age

  • BMI (body mass index)

  • ASA status classification

  • CCI (Charlson Comorbidity Index)

  • Inhalational anesthetics as MAC

  • Long lasting opioids as IV-morphine milligram equivalent including morphine, hydromorphone, methadone and sufentanil.

  • Use of neuraxial anesthesia

  • Intraoperative vasopressor dose

  • Intraoperative NMBA (neuromuscular blocking agent) dose

  • Intraoperative hypotension as number of minutes of an MAP (mean arterial pressure) <55 mmHG

  • Duration of surgery

  • Emergency status

  • Intraoperative fluids

  • PRBC (packed red blood cells) units

  • Work RVU [relative value unit]

  • Surgical service

  • Admission type (ambulatory vs inpatient)

  • SPORC (Score for Prediction of Postoperative Respiratory Complications)

  • SPOSA (Score for Prediction of Obstructive Sleep Apnea)

  • Inspiratory O2 - Fraction

  • Protective ventilation (defined as PEEP=5 and plateau pressure between 0 and 16)

  • Perioperative naloxone use

  • Prescription of any of the following opioids within 90 days prior to surgery: oxycodone, codeine, hydrocodone, buprenorphine, butorphanol, opium, hydromorphone, fentanyl, meperidine, morphine, levorphanol, methadone, nalbuphine, tapentadol, oxymorphone, roxicodone, tramadol

  • Code status (DNR)

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
183396 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effects of Intraoperative Fentanyl Dose on Postoperative Respiratory Complications
Actual Study Start Date :
Jan 1, 2007
Actual Primary Completion Date :
Dec 31, 2015
Anticipated Study Completion Date :
Jun 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Reference group

No fentanyl dose administered during surgery

Drug: Fentanyl dose administration

Comparative group

Fentanyl dose administered during surgery

Drug: Fentanyl dose administration

Outcome Measures

Primary Outcome Measures

  1. Postoperative respiratory complications [Between the day of surgery and the third day after surgery]

    New postoperative respiratory complications occuring within 3 days after surgery

Other Outcome Measures

  1. Post-extubation desaturation [Immediately after endotracheal extubation at the end of surgery]

    Oxygen saturation below 80% and 90% measured immediately after endotracheal extubation

  2. Non-invasive ventilation [Between the day of surgery and the third day after surgery]

    Incidence of non-invasive ventilation after surgery

  3. ICU admission rate [Between day of surgery and hospital discharge, may be up to one year]

    Admission to the ICU after surgery

  4. Hospital length of stay [Number of days between day of hospital admission and hospital discharge, may be up to one year]

    Total duration of hospitalized days

  5. Total hospital costs [Between day of hospital admission and hospital discharge, may be up to one year]

    Total costs for hospital stay

  6. Wound infection [Between the day of surgery and 30 days after surgery]

    Incidence of wound infection after surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Surgical patients at Massachusetts General Hospital and two affiliated community hospitals

  • 18 years of age and older

  • Only patients who required general anesthesia with an endotracheal tube for the surgical procedure and were extubated in the operating room at the end of the procedure.

Exclusion Criteria:
  • Brain dead patients (ASA greater than 5)

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Matthias Eikermann, Associate Professor of Anaesthesia, Harvard Medical School; Clinical Director, Critical Care Division, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT03198208
Other Study ID Numbers:
  • 2017P000825
First Posted:
Jun 26, 2017
Last Update Posted:
Jun 26, 2017
Last Verified:
Jun 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 26, 2017